![](/images/graphics-bg.png)
Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder
المؤلفون المشاركون
Reinke, Petra
Riess, Hanno
Zimmermann, Heiner
Weiland, Theresa
Nourse, Jamie P.
Gandhi, Maher K.
Neuhaus, Ruth
Karbasiyan, Mohsen
Gärtner, Barbara
Anagnostopoulos, Ioannis
Trappe, Ralf U.
Oertel, Stephan
المصدر
Journal of Immunology Research
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-02-10
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked to inferior outcome of rituximab monotherapy in B cell malignancies.
25 patients with PTLD after solid organ transplantation were included in this analysis.
They had received 4 weekly doses of rituximab as part of two clinical trials, which had a rituximab monotherapy induction regimen in common.
16/25 patients received further treatment with CHOP-21 after rituximab monotherapy (PTLD-1, NCT01458548).
The FCGR3A status was correlated to the response after 4 cycles of rituximab monotherapy.
Response to rituximab monotherapy was not affected by F carrier status.
This is in contrast to previous findings in B cell malignancies where investigators found a predictive impact of FCGR3A status on outcome to rituximab monotherapy.
One explanation for this finding could be that ADCC is impaired in transplant recipients receiving immunosuppression.
These results suggest that carrying a FCRG3A F allele does not negatively affect rituximab therapy in immunosuppressed patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zimmermann, Heiner& Weiland, Theresa& Nourse, Jamie P.& Gandhi, Maher K.& Reinke, Petra& Neuhaus, Ruth…[et al.]. 2014. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zimmermann, Heiner…[et al.]. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zimmermann, Heiner& Weiland, Theresa& Nourse, Jamie P.& Gandhi, Maher K.& Reinke, Petra& Neuhaus, Ruth…[et al.]. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1040807
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)